Inhibition of lymphoid tyrosine phosphatase by benzofuran salicylic acids.

The lymphoid tyrosine phosphatase (Lyp, PTPN22) is a critical negative regulator of T cell antigen receptor (TCR) signaling. A single-nucleotide polymorphism (SNP) in the ptpn22 gene correlates with the incidence of various autoimmune diseases, including type 1 diabetes, rheumatoid arthritis, and systemic lupus erythematosus. Since the disease-associated allele is a more potent inhibitor of TCR signaling, specific Lyp inhibitors may become valuable in treating autoimmunity. Using a structure-based approach, we synthesized a library of 34 compounds that inhibited Lyp with IC(50) values between 0.27 and 6.2 μM. A reporter assay was employed to screen for compounds that enhanced TCR signaling in cells, and several inhibitors displayed a dose-dependent, activating effect. Subsequent probing for Lyp's direct physiological targets by immunoblot analysis confirmed the ability of the compounds to inhibit Lyp in T cells. Selectivity profiling against closely related tyrosine phosphatases and in silico docking studies with the crystal structure of Lyp yielded valuable information for the design of Lyp-specific compounds.

[1]  N. Tonks,et al.  Protein tyrosine phosphatases: from genes, to function, to disease , 2006, Nature Reviews Molecular Cell Biology.

[2]  Sheng Zhang,et al.  PTP1B as a drug target: recent developments in PTP1B inhibitor discovery. , 2007, Drug discovery today.

[3]  K. Wood,et al.  Dual-Luciferase TM Reporter Assay: An Advanced Co-Reporter Technology Integrating Firefly and Renilla Luciferase Assays , 1996 .

[4]  Lutz Tautz,et al.  In Silico Screening for PTPN22 Inhibitors: Active Hits from an Inactive Phosphatase Conformation , 2009, ChemMedChem.

[5]  Nunzio Bottini,et al.  A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes , 2004, Nature Genetics.

[6]  Steven R. Williams,et al.  Identification of Substrates of Human Protein-tyrosine Phosphatase PTPN22* , 2006, Journal of Biological Chemistry.

[7]  E. Shaoul,et al.  Cloning and characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase, Lyp. , 1999, Blood.

[8]  Wen Hwa Lee,et al.  Large-Scale Structural Analysis of the Classical Human Protein Tyrosine Phosphatome , 2009, Cell.

[9]  T. Mustelin.  Keeping the T-cell immune response in balance: role of protein tyrosine phosphatases in autoimmunity. , 2002, Current directions in autoimmunity.

[10]  T. Mustelin,et al.  Targeting the PTPome in human disease , 2006, Expert opinion on therapeutic targets.

[11]  M. G. Finn,et al.  Click Chemistry: Diverse Chemical Function from a Few Good Reactions , 2001 .

[12]  Herbert Waldmann,et al.  Inhibitors of Protein Tyrosine Phosphatases: Next‐Generation Drugs? , 2005 .

[13]  A. Alonso,et al.  Inhibition of Yersinia Tyrosine Phosphatase by Furanyl Salicylate Compounds* , 2005, Journal of Biological Chemistry.

[14]  Andy Hudmon,et al.  Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-specific tyrosine phosphatase implicated in autoimmune diseases , 2007, Proceedings of the National Academy of Sciences.

[15]  D. Barford,et al.  Molecular basis for the dephosphorylation of the activation segment of the insulin receptor by protein tyrosine phosphatase 1B. , 2000, Molecular cell.

[16]  T. Mustelin,et al.  TCR-induced downregulation of protein tyrosine phosphatase PEST augments secondary T cell responses. , 2008, Molecular immunology.

[17]  Nunzio Bottini,et al.  Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant , 2005, Nature Genetics.

[18]  Joanna M. Sasin,et al.  Protein Tyrosine Phosphatases in the Human Genome , 2004, Cell.

[19]  D S Lawrence,et al.  Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase 1B: a paradigm for inhibitor design. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[20]  L. Klaman,et al.  Ertiprotafib Improves Glycemic Control and Lowers Lipids via Multiple Mechanisms , 2005, Molecular Pharmacology.

[21]  J. Bolen,et al.  Alterations of the lymphocyte-specific protein tyrosine kinase (p56lck) during T-cell activation , 1988, Molecular and cellular biology.

[22]  M. Amarzguioui,et al.  Short-Interfering RNA-Mediated Lck Knockdown Results in Augmented Downstream T Cell Responses1 , 2005, The Journal of Immunology.

[23]  Zhon-Yin Zhang,et al.  Targeting inactive enzyme conformation: aryl diketoacid derivatives as a new class of PTP1B inhibitors. , 2008, Journal of the American Chemical Society.

[24]  W. Rodgers,et al.  Exclusion of CD45 inhibits activity of p56lck associated with glycolipid-enriched membrane domains , 1996, The Journal of cell biology.

[25]  P. Johnson,et al.  Expression of CD45 alters phosphorylation of the lck-encoded tyrosine protein kinase in murine lymphoma T-cell lines. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Hardwick,et al.  The Activated Form of the Lck Tyrosine Protein Kinase in Cells Exposed to Hydrogen Peroxide Is Phosphorylated at Both Tyr-394 and Tyr-505* , 1997, The Journal of Biological Chemistry.